Compare
Vsee Health, Inc. vs Omada Health, Inc. vs GeneDx Holdings Corp. vs Pennant Group, Inc.
| Latest fiscal year | Vsee Health, Inc. VSEE | Omada Health, Inc. OMDA | GeneDx Holdings Corp. WGS | Pennant Group, Inc. PNTG |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $14.62M | $260.21M | $427.54M | $947.71M |
| Revenue growth (YoY) | +40.3% | +53.2% | +40.0% | +36.3% |
| Gross margin | 50.3% | 65.7% | 69.7% | n/a |
| Operating margin | -65.6% | -4.6% | -3.1% | 5.5% |
| Net margin | -100.6% | -4.9% | -4.9% | 3.1% |
| Net income | -$14.71M | -$12.78M | -$21.02M | $29.58M |
| EPS (Diluted) | -$0.73 | -$0.35 | -$0.73 | $0.84 |
| Operating cash flow | -$3.45M | $18.25M | $33.28M | $48.29M |
| Free cash flow | -$3.48M | $16.93M | $14.26M | $36.26M |
| Cash & equivalents | $5.27M | $222.04M | $105.00M | n/a |
| Total assets | $22.41M | $305.41M | $523.71M | $968.18M |
| Total liabilities | $16.96M | $75.73M | $215.53M | $593.93M |
| Shareholders' equity | $5.45M | $229.68M | $308.18M | $374.25M |
| Return on year-end equity | -269.8% | -5.6% | -6.8% | 7.9% |
| Shares outstanding | 33.19M | 58.43M | 29.25M | 34.63M |
Revenue, most recent five fiscal years
| Fiscal year | Vsee Health, Inc. | Omada Health, Inc. | GeneDx Holdings Corp. | Pennant Group, Inc. |
|---|---|---|---|---|
| Latest | $14.62M Ended 2025-12-31 | $260.21M Ended 2025-12-31 | $427.54M Ended 2025-12-31 | $947.71M Ended 2025-12-31 |
| 1 year earlier | $10.42M Ended 2024-12-31 | $169.80M Ended 2024-12-31 | $305.45M Ended 2024-12-31 | $695.24M Ended 2024-12-31 |
| 2 years earlier | $5.77M Ended 2023-12-31 | $122.78M Ended 2023-12-31 | $202.57M Ended 2023-12-31 | $544.89M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $234.69M Ended 2022-12-31 | $473.24M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $212.19M Ended 2021-12-31 | $439.69M Ended 2021-12-31 |